



Sheet 1 of 3

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0330/ AM101206(NP)	Application No. 10/659,167
		Applicant Dahui Zhou, et al.	
		Filing Date September 10, 2003	Group <u>1626</u> Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JK	1	Artigas, F., et al., "Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors," <i>Arch Gen Psychiatry</i> , March 1994, 51, 248-251	
JK	2	Blier, P., et al., "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression," <i>J. of Clinical Psychopharmacology</i> , 1995, 15(3), 217-222	
*	3	Bundgaard, (Ed.), Design of Prodrugs, Elsevier, 1985	
JK	4	Bundgaard, H., "Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs," <i>Advanced Drug Deliver Reviews</i> , 1992, 8, 1-38	
*	5	Bundgaard, J. of Pharmaceutical Sciences, 1988, 7(285 et seq.)	
JK	6	Cheetham, S.C., et al., "[³ H]paroxetine binding in rat frontal cortex strongly correlates with [³ H]5-HT uptake: effect of administration of various antidepressant treatments," <i>Neuropharmacol.</i> , 1993, 32(8), 737-743	
*	7	Eliel, E.L., Stereochemistry of Carbon Compounds, McGraw-Hill, NY, 1962	
JK	8	Hall, M.D., et al., "[³ H]8-hydroxy-2-(Di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain," <i>J. Neurochem.</i> , 1985, 44, 1685-1696	
*	9	Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems, American Chemical Society, 1975	
*	10	Jacques, et al., Enantiomers, Racemates and Resolutions, Wiley Interscience, NY, 1981	
EXAMINER <u>Kosack</u>		DATE CONSIDERED <u>1-3-06</u>	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0330/ AM101206(NP)	Application No. 10/659,167
		Applicant Dahui Zhou, et al.	
		Filing Date September 10, 2003	Group <u>1626</u> Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JK	11	Krogsgaard-Larsen, et al. (Eds.), "Design and Application of Prodrugs," <i>Textbook of Drug Design and Development</i> , 1991, Chap. 5, 113-191	
JK	12	Lazareno, S., et al., "Pharmacological characterization of acetylcholine-stimulated [³ S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies," <i>Br. J. Pharmacol.</i> , 1993, 109, 1120-1127	
JK	13	Ostrowski, S., "A synthesis of fused pyrimidine mono-n-oxides," <i>Heterocycles</i> , 1996, 43(2), page 389-396	
JK	14	Perez, V., et al., "Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment," <i>The Lancet</i> , May 31, 1997, 349, 1594-1597	
*	15	Remington's Pharmaceutical Sciences, 17th Ed., Gennaro, A.R. (Ed.), Mack Publishing Company, Easton, PA, 1985	
JK	16	Tome, M.B., et al., "Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and respons to paroxetine and pindolol," <i>J. Affect Disord.</i> , 1997, 44, 101-109	
JK	17	Tome, M.B., et al., "Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency," <i>Int. Clin. Psychopharmacol.</i> , 1997, 12, 81-89	
*	18	Widder, et al. (Eds.), Methods in Enzymology, Academic Press, 1985, Vol. 4	
JK	19	Wilens, S.H., "Tables of Resolving Agents and Optical Resolutions," <i>Univ. of Notre Dame Press, Notre Dame, IN</i> , E.L. Eliel (Ed.), 1972, page 268-298	
JK	20	Wilens, S.H., et al., "Strategies in optical resolutions," <i>Tetrahedron</i> , 1977, 33, 2725-2736	
EXAMINER <u>Kosack</u>		DATE CONSIDERED <u>1-3-06</u>	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0330/ AM101206(NP)	Application No. 10/659,167
	Applicant Dahui Zhou, et al.	
	Filing Date September 10, 2003	Group <i>1626</i> Not Yet Assigned
	Confirmation No. Not Yet Assigned	


U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
<i>JK</i>	<i>21</i>	WO 94/02477	02/03/94	PCT		
<i>JK</i>	<i>22</i>	WO 94/24125	10/27/94	PCT		
<i>JK</i>	<i>23</i>	WO 00/38677	07/06/00	PCT		

EXAMINER <i>Kosack</i>	DATE CONSIDERED <i>1-3-06</i>
------------------------	-------------------------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0330/ AM101206(NP)	Application No. 10/659,167
	Applicant Dahui Zhou and Gary Paul Stack	
	Filing Date September 10, 2003	Group 1614 1626
	Confirmation No. 3756	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
JK	24	2002/0183355 A1	12/05/02	Tran et al.	514	302

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
JK	25	0 559 285 A1	09/08/93	EP		
JK	26	0 771 800 A2	05/07/97	EP		
JK	27	0 963 983 A1	12/15/99	EP		
JK	28	02/072587 A1	09/19/02	WO		
JK	29	02/085911 A1	10/31/02	WO		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JK	30	Birch, A. M. et al., "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D ₂ Antagonists/5-HT _{1A} Partial Agonists with Potential as Atypical Antipsychotic Agents," <i>J Med Chem</i> , 1999, 42, 3342-3355

EXAMINER Kosack	DATE CONSIDERED 1-3-06
-----------------	------------------------